Tx360 and Intranasal Drug Delivery: What Providers Should Know | Dr. Tian Xia

How does the Tx360 nasal applicator deliver fluid to the sphenopalatine ganglion region, and what could this route mean for emerging intranasal research?

In this presentation from Regen Summit 2026, Dr. Tian Xia reviews the anatomy behind the Tx360 device, the sphenopalatine ganglion, trigeminal pathways, and proposed nose-to-brain delivery mechanisms. He also discusses preliminary observations involving an exosome-rich mesenchymal stem cell secretome in patients with neurological conditions.

Important: The neurological and exosome applications discussed remain investigational. No exosome product is FDA-approved to treat ALS or another neurological disorder, and preliminary observations do not establish safety or effectiveness. The device’s intended use also should not be interpreted as authorization for an exosome treatment or proof of delivery into the brain.

Want to be in the room next year? Get your Regen Summit 2027 tickets:
https://events.myinjectiontraining.com/summit2027/

Our content is for informational purposes only and should not be treated as medical or health advice. Please consult with your doctor/healthcare provider if you have any questions about your medical condition.

#IntranasalDelivery #Tx360 #RegenSummit